The total number of shares in Swedish Orphan Biovitrum AB (publ) as per 30 September 2013 amounts to 270,389,770 shares, whereof 265,226,598 common shares and 5,163,172 class C shares, corresponding to in total 265,742,915.2 votes. The increase in the number of shares and votes results from an issue of 754,912 class C shares under Swedish Orphan Biovitrum`s incentive program. The class C shares are intended to ensure fulfillment of commitments under incentive programs. The company holds all 5,163,172 class C shares.
Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (SOBI.ST) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com.
|For more information - not for publication|
|Media relations||Investor relations|
|Oskar Bosson, Head of Communications||Jörgen Winroth, Vice President, Head of Investor Relations|
|T: +46 70 410 71 80||T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135|
The above information has been made public in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was released for public distribution on 1 October 2013 at 08:30 CET.New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
- Investment & Company Information